Arie Regev received his MD degree from the Hebrew University in Jerusalem, Israel. He completed residency in Medicine and fellowship in Gastroenterology at Rabin Medical Center and Tel Aviv University and clinical fellowship in Hepatology and Transplant Hepatology at the University of Miami (UM), Florida. He continued working at UM as Associate Professor of Medicine and Director of the Hepatology fellowship program until 2007. He joined Eli Lilly in 2007, and currently heads Eli Lilly’s Safety Advisory Hub and chairs Eli Lilly’s Liver and GI Safety Committee. He is the author of numerous publications in major medical journals and several chapters in major medical textbooks. He is also an Associate Professor of Medicine at the Division of Gastroenterology and Hepatology of Indiana University School of Medicine. Arie Regev received his MD degree from the Hebrew University in Jerusalem, Israel. He completed residency in Medicine and fellowship in Gastroenterology at Rabin Medical Center and Tel Aviv University and clinical fellowship in Hepatology and Transplant Hepatology at the University of Miami (UM), Florida. He continued working at UM as Associate Professor of Medicine and Director of the Hepatology fellowship program until 2007. He joined Eli Lilly in 2007, and currently heads Eli Lilly’s Safety Advisory Hub and chairs Eli Lilly’s Liver and GI Safety Committee. He is the author of numerous publications in major medical journals and several chapters in major medical textbooks. He is also an Associate Professor of Medicine at the Division of Gastroenterology and Hepatology of Indiana University School of Medicine.

Smart Drug Delivery Technology Nano medicine and Drug Delivery Drug targeting Drug Design and Drug Formulation Anti-Cancer Drug Discovery